The bivalent prefusion F respiratory syncytial virus (RSVpreF) vaccine is effective against symptomatic RSV infection and viral shedding, new research in the New England Journal of Medicine found.
Tag: RSV respiratory syncytial virus
Respiratory syncytial virus (RSV) can increase risk of cardiovascular complications for individuals with and without preexisting cardiovascular disease.Read More
Pregnant women infected with respiratory syncytial virus (RSV) can transmit the bug from their respiratory tract to the lungs of their unborn baby – resulting in altered immunity development after birth.Read More
A collaborative group of researchers say they have developed double-stapled peptides that inhibit respiratory syncytial virus (RSV) in cells and in mice.Read More
The discovery could lead to new therapies and better diagnostics, resulting in fewer hospitalizations of children with respiratory syncytial virus, the most common cause of admission in children under the age of 1.Read More